When pharmaceutical companies use government incentives to raise prices unjustly, they fail their duty of care.
A better system for innovation on and access to health technologies is possible, driven by public health rather than profit.
Missing medicines and high prices
When pharmaceutical companies accept the incentives offered by national governments to incentivise innovation, they have a duty to serve public health – not only to line their pockets. However, they all too often do not fulfil this duty of care. See below for the broad challenges that get in the way of a better functioning health innovation system, and click on any category to explore more deeply.
Seeking innovation and access
There are solutions that can help refocus medical innovation where it needs to be – on patients, and their needs. For every challenge, there are ideas and proposals for improving the way that the system operates to ensure more equitable, affordable access to needed care. See below for potential solutions linked to the issue they address, and click on any category to explore more deeply.